← Eichor
Study identifier: NCT04116502 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Condition: Polycythemia Vera  ·  Sponsor: University of Birmingham

PhasePhase 3
Planned participants586
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.

This description comes directly from the study's public registry record.

Talk to the study team

Alex Hainsworth  ·  +44(0)121 414 2535  ·  mithridate@trials.bham.ac.uk

Always discuss trial participation with your own doctor first.

Locations (47)

Aberdeen Royal InfirmaryAberdeen, United KingdomRecruiting
Royal United HospitalBath, United KingdomRecruiting
Belfast City HospitalBelfast, United KingdomRecruiting
Birmingham Heartlands HospitalBirmingham, United KingdomRecruiting
Blackpool Victoria HospitalBlackpool, United KingdomRecruiting
Royal Bournemouth HospitalBournemouth, United KingdomRecruiting
Southmead HospitalBristol, United KingdomRecruiting
Addenbrooke's HospitalCambridge, United KingdomRecruiting
Kent and Canterbury HospitalCanterbury, United KingdomRecruiting
University Hospital of WalesCardiff, United KingdomRecruiting
St Richard's HospitalChichester, United KingdomRecruiting
Colchester HospitalColchester, United KingdomRecruiting

+ 35 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04116502